11 results about "Cardiac myocyte" patented technology

The invention is directed to a miRNA with a RNA sequence comprising or consisting of hsa-miR-4784 with SEQ ID NO: 6, or a member of the miR-4784 family, or a primary transcript thereof, a precursor thereof, a mimic thereof or a combination for use as a medicament, preferably for use in treatment of a cardiac disease associated with loss of cardiac myocytes.

The invention discloses application of Tongxinluo in preparation of a medicine capable of activating or enhancing a PERK-eIF2alpha-ATF4 signal channel. The medicine is used for treating or preventing diseases related to endoplasmic reticulum stress-mitochondrial autophagy axis dysfunction. The Tongxinluo regulates PINK1 / Parkin mediated mitochondrial autophagy by activating an eIF2alpha / ATF4 pathway, and can enhance selective elimination of damaged mitochondria while reducing the endoplasmic reticulum stress level of myocardial cells, so that heart remodeling is relieved, the diastolic function of the heart is improved, the symptom of the heart failure is relieved, and the progress of the heart failure is delayed.

The present invention discloses a staining agent, a method for preparing a heart section, and a method for evaluating microvascular perfusion staining. The mixed staining agent is used for microvascular perfusion staining, and the mixed staining agent includes DiIC 12 and DiIC 18 . In the mixed staining agent, the concentration ratio of DiIC 12 to DiIC 18 is 90-60:10-40. Experiments show that a certain proportion of the mixed staining agent can effectively solve the problems of poor solubility and uneven staining of DiIC 18 in coronary microcirculation perfusion staining, and does not affect the biological morphology and structure of myocardial cells and microvessels.

Disclosed herein are uses of polypeptides comprising NIMoEsh for treating diseases or conditions associated with acute myocardial infarction (AMI) in subjects in need thereof, uses of polypeptides comprising NIMoEsh for restoring cardiac function after AMI in subjects in need thereof, uses of polypeptides comprising NIMoEsh for reducing or preventing loss of cardiac function caused by AMI in subjects in need thereof, uses of polypeptides comprising NIMoEsh for reducing cardiac tissue infarction caused by AMI in subjects in need thereof, and uses of polypeptides comprising NIMoEsh for protecting cardiomyocytes from loss of function caused by AMI in subjects in need thereof. Also disclosed herein are methods for performing such treatment, restoration, reduction or prevention, reduction and / or protection, and polypeptides comprising NIMoEsh for such treatment, restoration, reduction or prevention, reduction and / or protection.

An engineered material includes a conductive biopolymer including a plurality of layers, each of which includes methacrylated hyaluronic acid conjugated with at least one of 3-thiophene acetic acid and with poly(3-thiophene) acetic acid; and myocytes. The myocytes can include iPSC-derived cardiomyocytes. The myocytes can be substantially aligned in single lines. The single lines can be approximately parallel to one another and approximately normal to planes defined by the plurality of layers. A method of 3D printing the layers is also described.

The present invention relates to compositions, methods, and devices for preventing irregular electromechanical waves in the myocardium that lead to pathological conditions as arrhythmia. In particular, the invention relates to compositions and methods to increase the conductivity of the myocardium to restore an impairment of the electrical conduction system of the heart. To that end substances with high conductivity, as carbon nanotube suspensions or metal nanowire suspensions, are injected in the myocardium at closely adjacent locations on circular or open lines or are introduced in patches of cardiomyocytes that are subsequently placed on the myocardium.

Provided herein are methods for producing quiescent cardiac fibroblast cells from pluripotent stem cells. Further provided herein are microtissue compositions comprising the cardiac fibroblast cells with endothelial cells and cardiomyocytes.

The present invention relates to compositions, methods, and devices for preventing irregular electromechanical waves in the myocardium that lead to pathological conditions as arrhythmia. In particular, the invention relates to compositions and methods to increase the conductivity of the myocardium to restore an impairment of the electrical conduction system of the heart. To that end substances with high conductivity, as carbon nanotube suspensions or metal nanowire suspensions, are injected in the myocardium at closely adjacent locations on circular or open lines or are introduced in patches of cardiomyocytes that are subsequently placed on the myocardium.

The invention discloses a 3-aryl coumarin derivative as well as a preparation method and application thereof, and the preparation method comprises the following steps: reacting substituted 2-bromobenzaldehyde with a substituted aryl acetic acid compound to obtain a substituted E-2, 3-diaryl acrylic acid compound; and in the presence of cuprous oxide and potassium carbonate, heating and reacting in N, N-dimethylformamide to obtain the 3-aryl coumarin derivative. The 3-aryl coumarin derivative disclosed by the invention can be combined with BRD4, has remarkable inhibitory activity on the BRD4, has a protective effect on primary myocardial cells caused by ischemia reperfusion, can inhibit proliferation, migration and invasion of cardiac fibroblasts, and can inhibit ferroptosis of hypoxia / reperfusion injury myocardial cells; the compound can be used for preparing medicines for treating diseases related to abnormal BRD4 activity.

This invention belongs to the fields of pharmaceutical formulation and nanomedicine technology, and discloses a biomimetic nanomedicine for the prevention and treatment of dilated cardiomyopathy and its preparation method. The core of this invention is reactive oxygen species (ROS) responsive / scavenging nanomicelles (TPTN), which are prepared into a biomimetic nanocomposite (MTPTN) by encapsulating the mitochondrial outer membrane with TPTN through co-extrusion. This biomimetic nanomedicine can effectively cross the damaged vascular endothelial barrier and target and accumulate at the site of cardiac lesions. It utilizes the cell / intracellular transport mechanism mediated by mitochondrial outer membrane surface proteins and homologous targeting to achieve targeted enrichment of mitochondria in damaged cardiomyocytes. The encapsulated ROS responsive / scavenging nanomicelles TPTN can effectively remove excess ROS at the lesion site, inhibit inflammatory infiltration, and thus prevent and treat the occurrence and development of dilated cardiomyopathy.

As a technology for enriching atrial myocytes or ventricular myocytes in a cardiomyocyte-containing cell population induced from stem cells, provided is a method for enriching atrial myocytes or ventricular myocytes in a cardiomyocyte-containing cell population induced from stem cells, the method including a step of collecting atrial myocytes or ventricular myocytes from the cell population by using the expression level of CD151 as an index.